RxDoctor Payments Data

John Tauro, DO

Neuromuscular Medicine · Norwich, CTNPI 1003915778

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,375 of the $53,731 with a category attached, or 62.1%. AbbVie accounts for 76.9% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2020 at $14,723 and has fallen 69.0% since, to $4,565 in 2025.

$53,731in general payments, 2019–2025

Across 951 payments — averaging $56.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Pfizer$2K
  • UCB, Inc.$846
  • Teva Pharmaceuticals USA, Inc.$647
  • Lundbeck LLC$621
  • Amgen$585
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$33,37562%
  • Travel & lodging$1,8053%
  • Food & beverage$18,52534%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)331$41,305
Pfizer73$1,627
UCB, Inc.33$846
Teva Pharmaceuticals USA, Inc.38$647
Lundbeck LLC26$621
Amgen(2 entities)29$585
Biogen27$565
AstraZeneca(2 entities)25$529
Sanofi29$489
Biohaven Pharmaceutical Holding Company Ltd.22$475
CSL Behring22$436
Takeda Pharmaceuticals U.S.A., Inc.17$389
SK Life Science, Inc.14$368
Sunovion Pharmaceuticals Inc.29$359
EMD Serono, Inc.13$331
Eisai Inc.15$327
Novartis23$297
Genentech USA, Inc.13$283
Octapharma USA, Inc.12$279
Biohaven Pharmaceuticals, Inc.15$269
Avanir Pharmaceuticals, Inc.14$255
Johnson & Johnson(2 entities)9$189
Lilly USA, LLC10$176
Scilex Pharmaceuticals Inc.8$175
Argenx US, Inc.7$167
Mallinckrodt Hospital Products Inc.7$135
Amneal Pharmaceuticals LLC7$116
Tanabe Pharma America, Inc.6$112
Grifols USA, LLC6$101
Impel Pharmaceuticals Inc.6$84
Axsome Therapeutics, Inc.4$78
Cycle Pharmaceuticals Inc4$78
Bristol Myers Squibb3$73
Alnylam Pharmaceuticals Inc.4$69
Neurocrine Biosciences, Inc.3$63
Currax Pharmaceuticals LLC4$59
Otsuka America Pharmaceutical, Inc.3$58
TG Therapeutics, Inc.2$53
Supernus Pharmaceuticals, Inc.4$52
Mallinckrodt Enterprises LLC2$52
Ipsen Biopharmaceuticals, Inc3$52
Averitas Pharma Inc.2$45
Kyowa Kirin, Inc.2$42
Upsher-smith Laboratories LLC3$42
Life Molecular Imaging Ltd3$35
Almatica Pharma LLC2$34
Sumitomo Pharma America, Inc.3$32
GE HealthCare1$30
Assertio Therapeutics, Inc.2$29
Vanda Pharmaceuticals Inc.1$28
ANI Pharmaceuticals, Inc.1$23
Collegium Pharmaceutical, Inc.1$22
Catalyst Pharmaceuticals, Inc.1$22
Banner Life Sciences, LLC1$21
Sanofi-aventis U.S. LLC1$19
Tonix Medicines, Inc.1$19
Amylyx Pharmaceuticals, Inc.1$18
Kedrion Biopharma, Inc.1$17
Neurelis, Inc.1$15
Merz Pharmaceuticals, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$168,676
Medicare patients
241
Services billed
32,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab17$1,070,663
Gamunex-CImmune Globul G/Gly/Iga Avg 4693$737,003
OctagamImmun Globg(Igg)/Malt/Iga Ov5026$446,717
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5030$149,539
BotoxOnabotulinumtoxina74$115,287
MestinonPyridostigmine Bromide11$43,666
Aimovig AutoinjectorErenumab-Aooe32$27,070
QuliptaAtogepant13$26,901
Nurtec OdtRimegepant Sulfate13$23,926
UbrelvyUbrogepant17$16,107
DepakoteDivalproex Sodium11$15,057
Ajovy AutoinjectorFremanezumab-Vfrm12$12,401
Tegretol XrCarbamazepine18$8,409
Gabapentin124$3,298
Pyridostigmine Bromide36$3,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$167$1,070,66317 claims
Grifols USA, LLCGamunex-C$101$737,00393 claims
PfizerOctagam, Nurtec Odt$1,627$470,64239 claims
AbbVieBotox, Qulipta, Ubrelvy$41,305$158,295104 claims
CSL BehringPrivigen$436$149,53930 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$116$3,13536 claims
Upsher-smith Laboratories LLCTopiramate$42$11521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →